Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-10-23
Target enrollment:
Participant gender:
Summary
This phase I trial studies the long-term side effects of the continuation of oral ONC201 in
treating patients with solid tumors that have spread to other places in the body who have
previously benefited from receiving this drug. Oral ONC201 may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.
Phase:
Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Oncoceutics, Inc. Rutgers Cancer Institute of New Jersey